Baird Boosts Price Target on Regeneron (REGN) as Survey Indicates Positive Eylea Momentum

Article Related Press Releases (1) Stock Quotes (1) Comments (0)

Baird reiterated an Outperform rating Regeneron Pharma (NASDAQ: REGN) and raised its price target to $175.00 (from $150.00).

"We remain REGN buyers in front of the company's Q312 earnings report as new survey data indicates positive Eylea momentum continues. Given this feedback, we are raising our Eylea estimates once again to levels well ahead of current 2012 guidance and 2012-2015 consensus," said analyst Christopher J. Raymond.

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $158.07 yesterday, with a 52 week range of $49.58-$158.51.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Jefferies Bumps Zumiez (ZUMZ) Numbers Up, But Remains on Sidelines
• Needham & Company Boosts Numbers on Infoblox (BLOX) on Strong Q3
• Wells Fargo Boosts Price Target on Pandora (P), Maintains Outperform

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

Robert W Baird, Earnings

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?